Ebola vaccine race: Moderna and rivals push mRNA breakthrough amid Bundibugyo outbreak

Amid a surge of Bundibugyo virus cases, the global scientific community is accelerating efforts to bring an Ebola vaccine to market.

Ebola vaccine race intensifies as mRNA platforms take lead

Moderna, partnered with the Coalition for Epidemic Preparedness Innovations, is testing a messenger‑RNA candidate while rivals such as BioNTech and Inovio scramble to file their own protocols. Reuters notes that regulatory pathways have been streamlined to cut months off development.

“We aim to deliver a safe, effective solution within months,” said a Moderna spokesperson.

Early animal trials show ↑ 90% neutralizing antibody response, a promising sign for human phases.

Intel provided by Elena Rostova (Socio-Economic Trends Analyst).